Novo Nordisk has been riding a wave of success in recent years, due in large part to GLP 1 analog semaglutide – but now is not the time to slack off on the work to bring new drugs to market, says Novo Nordisk’s CFO, Karsten Munk Knudsen at a teleconference on Wednesday in connection with the release of Novo’s 2021 financial figures.
”The way it works in the pharmaceutical industry is that you have to have innovation when you are benefitting strongly from sales of your products, so there are products ready to take over once the oldest products begin to sell less,” the CFO said.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Rumored GN purchase unlikely but not impossible, say analysts
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
EMA begins analyzing Bavarian Nordic's vaccine against monkeypox
Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Bavarian Nordic eyes European monkeypox approval for smallpox vaccine
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.
New CFO wants to shake things up at WSA
A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.
Chinese patent expiration dates draw closer for Novo Nordisk
In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
Chemist for Incoming Materials in QC Department 
Nordic Medical Affairs Manager 
Biomarker Operations Lead 
Director for innovative pre-clinical testing unit 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Senior Manager, Clinical Trial Budget 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Senior Project Manager (GMP - Life Science) 
Senior QA Specialist 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Senior Chemical Safety Advisor 
Production Director 
Account Manager 
Client Talent Acquisition Specialist 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Trial Manager 
Communications Consultant 
Clinical Trial Manager for development of in vitro diagnostics 
Key Account Manager, Europe and Asia